Watch Demo

Brain Cancer Diagnostics Market Research Report by Test Type, Brain Cancer Type, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

Brain Cancer Diagnostics Market Research Report by Test Type, Brain Cancer Type, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:242

  • Report ID:6388747

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Brain Cancer Diagnostics Market Research Report by Test Type (Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, and PET Scan), Brain Cancer Type, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

The Global Brain Cancer Diagnostics Market size was estimated at USD 3,583.20 million in 2022 and expected to reach USD 4,023.43 million in 2023, projecting growth at a CAGR of 12.42% to reach USD 9,143.40 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Brain Cancer Diagnostics Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Brain Cancer Diagnostics Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Brain Cancer Diagnostics Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Brain Cancer Diagnostics Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the Global Brain Cancer Diagnostics Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Test Type, the market is studied across Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan, and Spinal Tap.

Based on Brain Cancer Type, the market is studied across Acoustic Neuroma, Astrocytomas, Chordomas, and Ependymomas.

Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Brain Cancer Diagnostics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Brain Cancer Diagnostics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Brain Cancer Diagnostics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Brain Cancer Diagnostics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Brain Cancer Diagnostics Market, including Abbott Laboratories, Associated Regional and University Pathologists, Inc., Becton, Dickinson and Company, Bristol Myers Squibb Co, F. Hoffmann-La Roche AG, Fujifilm Corporation, GE Healthcare, Hitachi, Ltd., Hologic, Inc., Illumina, Inc., Invitae Corporation, Koninklijke Philips N.V., NantOmics, NeoGenomics Laboratories, Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Brain Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Brain Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Brain Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the Global Brain Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Brain Cancer Diagnostics Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of brain cancer
5.1.1.2. Growth in the number of private diagnostic centers and rising public-private partnerships
5.1.2. Restraints
5.1.2.1. Heavy costs associated with diagnosis and low awareness about the diagnosis
5.1.3. Opportunities
5.1.3.1. Technological advancement in diagnostics devices
5.1.3.2. Development of diagnostic approaches for various cancer mutations
5.1.4. Challenges
5.1.4.1. Rising risk of high radiation exposure and stringent regulatory guidelines
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Brain Cancer Diagnostics Market, by Test Type
6.1. Introduction
6.2. Magnetic Resonance Imaging
6.3. Magnetic Resonance Spectroscopy
6.4. PET Scan
6.5. Spinal Tap

7. Brain Cancer Diagnostics Market, by Brain Cancer Type
7.1. Introduction
7.2. Acoustic Neuroma
7.3. Astrocytomas
7.4. Chordomas
7.5. Ependymomas

8. Americas Brain Cancer Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Brain Cancer Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Brain Cancer Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Product Portfolio Analysis, By Key Player
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Abbott Laboratories
12.2. Associated Regional and University Pathologists, Inc.
12.3. Becton, Dickinson and Company
12.4. Bristol Myers Squibb Co
12.5. F. Hoffmann-La Roche AG
12.6. Fujifilm Corporation
12.7. GE Healthcare
12.8. Hitachi, Ltd.
12.9. Hologic, Inc.
12.10. Illumina, Inc.
12.11. Invitae Corporation
12.12. Koninklijke Philips N.V.
12.13. NantOmics
12.14. NeoGenomics Laboratories, Inc.
12.15. Siemens Healthineers AG
12.16. Thermo Fisher Scientific, Inc.

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET DYNAMICS
FIGURE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2030 (%)
FIGURE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TEST TYPE, 2030
FIGURE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, 2018-2030 (USD MILLION)
FIGURE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2022 VS 2030 (%)
FIGURE 20. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY BRAIN CANCER TYPE, 2030
FIGURE 22. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, 2018-2030 (USD MILLION)
FIGURE 25. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, 2018-2030 (USD MILLION)
FIGURE 26. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 27. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 28. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 29. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 30. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 31. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 32. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 33. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 34. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 35. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 36. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 37. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 38. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 40. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 41. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 42. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 46. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 56. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 57. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 58. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 80. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 81. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 42. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 43. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 45. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 46. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 47. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 59. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 60. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 61. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 62. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 63. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 64. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 68. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 69. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 74. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 77. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 78. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 80. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 81. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 82. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 83. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 84. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 85. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 86. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 87. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 88. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 89. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 90. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 91. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 96. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 97. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 98. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 99. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 100. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 101. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 102. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 103. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 104. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 105. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 106. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 107. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 108. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 109. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 110. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 111. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 112. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 113. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 114. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 115. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 116. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 117. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 118. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 119. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 120. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 121. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 122. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 123. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 124. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 125. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 126. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 127. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 128. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 129. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 130. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 131. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 138. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 139. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 141. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 142. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 143. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 144. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 145. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 146. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 147. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 148. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 149. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 150. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 151. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 152. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 159. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 160. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 161. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 162. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 163. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 164. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 165. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET MERGER & ACQUISITION
TABLE 166. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 167. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 168. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET INVESTMENT & FUNDING
TABLE 169. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 170. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Associated Regional and University Pathologists, Inc.
Becton, Dickinson and Company
Bristol Myers Squibb Co
F. Hoffmann-La Roche AG
Fujifilm Corporation
GE Healthcare
Hitachi, Ltd.
Hologic, Inc.
Illumina, Inc.
Invitae Corporation
Koninklijke Philips N.V.
NantOmics
NeoGenomics Laboratories, Inc.
Siemens Healthineers AG
Thermo Fisher Scientific, Inc.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.